Volume Alert - OXGN 2.01 Oxigene Inc $OXGN Hit a high today of 2.15 Closing the day 10:30 at 2.01 +0.03 +1.52% With a day low of 1.97 and a total volume of 871,476.
OXGN Recent Posts: http://investorshangout.com/OXiGENE-Inc-OXGN-55032/
OXGN Oxigene Inc Recent Headline News
Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against?
Clinically Sound Investor - at Seeking Alpha - 2 hrs 58 mins ago
OXGN: 1.87 (-0.11)
OXiGENE: Q3 Earnings And Avastin Approval, Bull Thesis Reiterated
Trevor Lowenthal - at Seeking Alpha - Fri Nov 14, 3:20PM CST
OXGN: 1.87 (-0.11)
Oxigene: Why I Think This Risky Biotech Is A Speculative Buy
Daniel Ward - at Seeking Alpha - Fri Nov 14, 8:15AM CST
OXGN: 1.87 (-0.11)
OXiGENE (OXGN) CEO Dr. Dave Chaplin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 8:27PM CST
OXGN: 1.87 (-0.11)
OXiGENE (OXGN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 12, 3:25PM CST
OXGN: 1.87 (-0.11)
OXiGENE beats by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:05PM CST
OXGN: 1.87 (-0.11)
OXiGENE Reports Third Quarter 2014 Financial Results
GlobeNewswire - Wed Nov 12, 3:02PM CST
- Positive Data from the Phase 2 GOG 186I Study in Ovarian Cancer Presented at Major Conference -
OXGN: 1.87 (-0.11)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:18AM CST
ANV: 1.60 (+0.23), KEP: 20.36 (-0.20), RADA: 2.38 (-0.17), SEAS: 16.96 (+0.05), HPJ: 6.10 (-0.13), PLUG: 3.71 (-0.01), SUPN: 8.35 (-0.12), NBG: 2.18 (-0.04), GV: 2.06 (+0.03), OXGN: 1.87 (-0.11), NOAH: 16.79 (-0.38), FOSL: 107.11 (-1.21), AEO: 13.52 (+0.02), IBIO: 1.09 (+0.04), MTOR: 14.08 (-0.02), MLNX: 42.42 (-0.48), SUSQ: 13.06 (-0.09)
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data
at The Street - Wed Nov 12, 4:12AM CST
An analysis of results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer.
OXGN: 1.87 (-0.11), GSK: 45.86 (+0.12)
Update: OXiGENE Presents Zybrestat/Avastin Data, Bull Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Tue Nov 11, 4:56AM CST
OXGN: 1.87 (-0.11)
Stock to Watch: OXiGENE Down 6.9% (OXGN)
Comtex SmarTrend(R) - Mon Nov 10, 11:59AM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 6.9% to $2.01 on 1.0x average daily volume. Thus far today, OXiGENE has traded 694,000 shares, vs. average volume of 663,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.2%) and underperformed the S&P 500 (-6.9% to the S&P's 0.3%) during today's trading.
OXGN: 1.87 (-0.11)
OxiGene presents Phase 2 data on fosbretabulin
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:31AM CST
OXGN: 1.87 (-0.11)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.62 (-0.03), IMGN: 9.25 (-0.28), AMGN: 159.37 (+1.69), LLY: 67.31 (-0.02), ONTX: 4.67 (-0.02), BMY: 58.40 (+0.45), GSK: 45.86 (+0.12), OXGN: 1.87 (-0.11), XLRN: 32.94 (-0.56), KPTI: 40.66 (+0.89), NVS: 94.42 (+0.47)
OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer
GlobeNewswire - Mon Nov 10, 2:00AM CST
- Subgroup Analysis of GOG 186I Study Shows Benefit in Difficult-to-Treat Platinum-Resistant Patients -
OXGN: 1.87 (-0.11)
OXiGENE Down 5.8%, Shares Slide into the Red (OXGN)
Comtex SmarTrend(R) - Thu Nov 06, 10:09AM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 5.8% to $2.27 on 1.3x average daily volume. Thus far today, OXiGENE has traded 783,000 shares, vs. average volume of 600,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.5%) and underperformed the S&P 500 (-5.8% to the S&P's 0.3%) during today's trading.
OXGN: 1.87 (-0.11)
Lower Your Expectations For OXiGENE's Presentation At The November 8 International Gynecologic Cancer Society Meeting
Clinically Sound Investor - at Seeking Alpha - Thu Nov 06, 9:15AM CST
OXGN: 1.87 (-0.11)
OXiGENE Up 5.6%, Shares Break Through Resistance (OXGN)
Comtex SmarTrend(R) - Mon Oct 27, 11:36AM CDT
OXiGENE (NASDAQ:OXGN) is one of today's best performing low-priced stocks, up 5.6% to $2.27 on 1.3x average daily volume. Thus far today, OXiGENE has traded 594,000 shares, vs. average volume of 440,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's -0.2%) and outperformed the S&P 500 (5.6% to the S&P's -0.4%) during today's trading.
OXGN: 1.87 (-0.11)
Traders Get Bullish on Shares of OXiGENE, Shares Up 6.1% (OXGN)
Comtex SmarTrend(R) - Fri Oct 24, 10:08AM CDT
OXiGENE (NASDAQ:OXGN) is one of today's best performing low-priced stocks, up 6.1% to $2.09 on 1.8x average daily volume. Thus far today, OXiGENE has traded 801,000 shares, vs. average volume of 447,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's 0.3%) and outperformed the S&P 500 (6.1% to the S&P's 0.3%) during today's trading.
OXGN: 1.87 (-0.11)
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta
at The Street - Fri Oct 24, 7:28AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.87 (-0.11), RNA: 11.40 (+0.13), SRPT: 15.19 (-0.13), RMTI: 10.55 (+0.03)
OXGN Recent Posts: http://investorshangout.com/OXiGENE-Inc-OXGN-55032/
OXGN Oxigene Inc Recent Headline News
Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against?
Clinically Sound Investor - at Seeking Alpha - 2 hrs 58 mins ago
OXGN: 1.87 (-0.11)
OXiGENE: Q3 Earnings And Avastin Approval, Bull Thesis Reiterated
Trevor Lowenthal - at Seeking Alpha - Fri Nov 14, 3:20PM CST
OXGN: 1.87 (-0.11)
Oxigene: Why I Think This Risky Biotech Is A Speculative Buy
Daniel Ward - at Seeking Alpha - Fri Nov 14, 8:15AM CST
OXGN: 1.87 (-0.11)
OXiGENE (OXGN) CEO Dr. Dave Chaplin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 8:27PM CST
OXGN: 1.87 (-0.11)
OXiGENE (OXGN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 12, 3:25PM CST
OXGN: 1.87 (-0.11)
OXiGENE beats by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:05PM CST
OXGN: 1.87 (-0.11)
OXiGENE Reports Third Quarter 2014 Financial Results
GlobeNewswire - Wed Nov 12, 3:02PM CST
- Positive Data from the Phase 2 GOG 186I Study in Ovarian Cancer Presented at Major Conference -
OXGN: 1.87 (-0.11)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:18AM CST
ANV: 1.60 (+0.23), KEP: 20.36 (-0.20), RADA: 2.38 (-0.17), SEAS: 16.96 (+0.05), HPJ: 6.10 (-0.13), PLUG: 3.71 (-0.01), SUPN: 8.35 (-0.12), NBG: 2.18 (-0.04), GV: 2.06 (+0.03), OXGN: 1.87 (-0.11), NOAH: 16.79 (-0.38), FOSL: 107.11 (-1.21), AEO: 13.52 (+0.02), IBIO: 1.09 (+0.04), MTOR: 14.08 (-0.02), MLNX: 42.42 (-0.48), SUSQ: 13.06 (-0.09)
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data
at The Street - Wed Nov 12, 4:12AM CST
An analysis of results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer.
OXGN: 1.87 (-0.11), GSK: 45.86 (+0.12)
Update: OXiGENE Presents Zybrestat/Avastin Data, Bull Thesis Remains Intact
Trevor Lowenthal - at Seeking Alpha - Tue Nov 11, 4:56AM CST
OXGN: 1.87 (-0.11)
Stock to Watch: OXiGENE Down 6.9% (OXGN)
Comtex SmarTrend(R) - Mon Nov 10, 11:59AM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 6.9% to $2.01 on 1.0x average daily volume. Thus far today, OXiGENE has traded 694,000 shares, vs. average volume of 663,000 shares per day. The stock has underperformed the Dow (-6.9% to the Dow's 0.2%) and underperformed the S&P 500 (-6.9% to the S&P's 0.3%) during today's trading.
OXGN: 1.87 (-0.11)
OxiGene presents Phase 2 data on fosbretabulin
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:31AM CST
OXGN: 1.87 (-0.11)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.62 (-0.03), IMGN: 9.25 (-0.28), AMGN: 159.37 (+1.69), LLY: 67.31 (-0.02), ONTX: 4.67 (-0.02), BMY: 58.40 (+0.45), GSK: 45.86 (+0.12), OXGN: 1.87 (-0.11), XLRN: 32.94 (-0.56), KPTI: 40.66 (+0.89), NVS: 94.42 (+0.47)
OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer
GlobeNewswire - Mon Nov 10, 2:00AM CST
- Subgroup Analysis of GOG 186I Study Shows Benefit in Difficult-to-Treat Platinum-Resistant Patients -
OXGN: 1.87 (-0.11)
OXiGENE Down 5.8%, Shares Slide into the Red (OXGN)
Comtex SmarTrend(R) - Thu Nov 06, 10:09AM CST
OXiGENE (NASDAQ:OXGN) is one of today's worst performing low-priced stocks, down 5.8% to $2.27 on 1.3x average daily volume. Thus far today, OXiGENE has traded 783,000 shares, vs. average volume of 600,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.5%) and underperformed the S&P 500 (-5.8% to the S&P's 0.3%) during today's trading.
OXGN: 1.87 (-0.11)
Lower Your Expectations For OXiGENE's Presentation At The November 8 International Gynecologic Cancer Society Meeting
Clinically Sound Investor - at Seeking Alpha - Thu Nov 06, 9:15AM CST
OXGN: 1.87 (-0.11)
OXiGENE Up 5.6%, Shares Break Through Resistance (OXGN)
Comtex SmarTrend(R) - Mon Oct 27, 11:36AM CDT
OXiGENE (NASDAQ:OXGN) is one of today's best performing low-priced stocks, up 5.6% to $2.27 on 1.3x average daily volume. Thus far today, OXiGENE has traded 594,000 shares, vs. average volume of 440,000 shares per day. The stock has outperformed the Dow (5.6% to the Dow's -0.2%) and outperformed the S&P 500 (5.6% to the S&P's -0.4%) during today's trading.
OXGN: 1.87 (-0.11)
Traders Get Bullish on Shares of OXiGENE, Shares Up 6.1% (OXGN)
Comtex SmarTrend(R) - Fri Oct 24, 10:08AM CDT
OXiGENE (NASDAQ:OXGN) is one of today's best performing low-priced stocks, up 6.1% to $2.09 on 1.8x average daily volume. Thus far today, OXiGENE has traded 801,000 shares, vs. average volume of 447,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's 0.3%) and outperformed the S&P 500 (6.1% to the S&P's 0.3%) during today's trading.
OXGN: 1.87 (-0.11)
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta
at The Street - Fri Oct 24, 7:28AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.87 (-0.11), RNA: 11.40 (+0.13), SRPT: 15.19 (-0.13), RMTI: 10.55 (+0.03)
